From Yahoo Finance: 2025-03-22 09:37:00

JPMorgan analyst Jessica Fye lowered Moderna’s price target to $33 from $40, citing more conservative RSV and influenza estimates. The firm now models 2025 RSV sales at $148M, versus a prior estimate of $210M. For FY25, total revenue is now estimated at $2.1B, slightly above consensus and guidance midpoint.

For more real-time financial news, visit TheFly. See insider trading stocks on TipRanks for the latest updates on MRNA. Contact [email protected] for questions or comments about the article.

Read more: Moderna price target lowered to $33 from $40 at JPMorgan